Parmar M

ORCID: 0000-0001-7818-4100 · 5 papers in corpus · active 2015-2025
2025
Nature medicine ·doi:10.1038/s41591-025-03763-y

Use of signal transduction inhibitors as single agents to treat cancer leads to resistance because of the plasticity of intracellular signaling, and combination therapy can overcome this. We describe the first-in-human trial of avutometinib…

2022
BJOG : an international journal of obstetrics and gynaecology ·doi:10.1111/1471-0528.16943

ObjectiveTo investigate the association between hysterectomy with conservation of one or both adnexa and ovarian and tubal cancer.DesignProspective cohort study.SettingThirteen NHS Trusts in England, Wales and Northern Ireland.PopulationA t…

2020
Cancers ·doi:10.3390/cancers12071931

Longitudinal CA125 algorithms are the current basis of ovarian cancer screening. We report on longitudinal algorithms incorporating multiple markers. In the multimodal arm of United Kingdom Collaborative Trial of Ovarian Cancer Screening (U…

2018
F1000Research ·doi:10.12688/f1000research.15663.1

Background: We report on a unique audit of seven sonographers self-reporting high visualization rates of normal postmenopausal ovaries in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).  This audit was ordered …

2015
Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·doi:10.1200/jco.2014.59.4945

PurposeCancer screening strategies have commonly adopted single-biomarker thresholds to identify abnormality. We investigated the impact of serial biomarker change interpreted through a risk algorithm on cancer detection rates.Patients and …